In CLL patients, weak and moderate correlations between the cell resistance to doxorubicin and the expression of the unfavorable prognostic marker, CD38 [59] (r = 0.23); the proliferation marker, Ki-67 (r = 0.12); and the immaturity marker, HLA-DR (r = 0.43), were found (Table S8). Here, CD38 is linked to B-cell chronic lymphocytic leukemia.